This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Lui, S L Articles by Lai, K N Search for Related Content PubMed PubMed Citation Articles by Lui, S L Articles by Lai, K N Social Bookmarking                   What's this?

Effect of mycophenolate mofetil on severity of nephritis and nitric oxide production in lupus-prone MRL/lpr mice

Division of Nephrology, University Department of Medicine, Queen Mary Hospital, Pokfulam, Hong Kong, Republic of China. sllui{at}hkucc.hku.hk

R Tsang

Division of Nephrology, University Department of Medicine, Queen Mary Hospital, Hong Kong, Republic of China

D Wong

Division of Medical Physics, University Department of Medicine, Queen Mary Hospital, Hong Kong, Republic of China

K W Chan

University Department of Pathology, Queen Mary Hospital, Hong Kong, Republic of China

T M Chan

Division of Nephrology, University Department of Medicine, Queen Mary Hospital, Hong Kong, Republic of China

P C W Fung

Division of Medical Physics, University Department of Medicine, Queen Mary Hospital, Hong Kong, Republic of China

K N Lai

Division of Nephrology, University Department of Medicine, Queen Mary Hospital, Hong Kong, Republic of China

Mycophenolate mofetil (MMF), an immunosuppressive drug commonly used in organ transplantation, is increasingly being used to treat autoimmune diseases including systemic lupus erythematosus (SLE). Excessive production of nitric oxide (NO) by inducible nitric oxide synthase (iNOS) has been implicated in the pathogenesisof lupus nephritis. We evaluated the effect of MMF on the severity of nephritis and the production of NO in lupus-prone MRL/lpr mice.

Eight-week-old female MRL/lpr mice (n = 20) were treated with MMF (100 mg/kg/day) by oral gavage for 12 weeks. Control mice (n = 20) received vehicle on the same schedule. The mice were killed after 12 weeks of treatment. Treatment with MMF significantly decreased the amount of proteinuria, prolonged survival and reduced the histological severity of glomerulonephritis.Urinary nitrite/nitrate excretion in the MMF-treated mice was significantly reduced during the first 8 weeks of treatment. However, by the end of the 12 weeks' treatment period, there was no significant difference between vehicle and MMF-treated mice in terms of urinary nitrite/nitrate excretion, intra-renal production of NO, expression of iNOS protein and induction of iNOS mRNA.

We conclude that MMF is effective in attenuatingthe severity of nephritis in MRL/lpr mice. The beneficial effects of MMF on lupus nephritis during the early phase of the disease might be partly attributed to the inhibition of NO production. The inhibitory effect of MMF on NO production diminishes as the disease progresses. MMF probably has additional, as yet undefined mode of actions to fully account for its beneficial effects on lupus nephritis.

Key Words: mycophenolate mofetil • nitric oxide • renal • systemic lupus erythematosus

Lupus, Vol. 11, No. 7, 411-418 (2002)
DOI: 10.1191/0961203302lu214oa


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				W T Gibson and M R Hayden Mycophenolate mofetil and animal models Lupus, November 1, 2006; 15(11_suppl): 27 - 34. [Abstract] [PDF]

				G Zandman-Goddard and Y Shoenfeld Mycophenolate mofetil in animal models of autoimmune disease Lupus, March 1, 2005; 14(3_suppl): s12 - s16. [Abstract] [PDF]

				M J Lewis and D D'Cruz Adhesion molecules, mycophenolate mofetil and systemic lupus erythematosus Lupus, March 1, 2005; 14(3_suppl): s17 - s26. [Abstract] [PDF]

				E M Ginzler and C Aranow Mycophenolate mofetil in lupus nephritis Lupus, January 1, 2005; 14(1): 59 - 64. [Abstract] [PDF]

				G. Zandman-Goddard and Y. Shoenfeld Mycophenolate mofetil in animal models of autoimmune disease Lupus, January 1, 2005; 14(1_suppl): s12 - s16. [Abstract] [PDF]

				M. Lewis and D. D'Cruz Adhesion molecules, mycophenolate mofetil and systemic lupus erythematosus Lupus, January 1, 2005; 14(1_suppl): s17 - s26. [Abstract] [PDF]